Rift valley fever (RVF) has been experienced both in Eastern and Southern Africa regions and beyond since its discovery and isolation of the virus. The current controlmeasures include application of animal vaccines: live attenuated Smithburn and inactivated vaccines. They have their own shortcomings and challenges when
applied under prevailing field conditions. The mode of vaccine application and regulations of these vaccines are dependent on the existing national policies.
GALVmed is supporting the development of safe and efficacious RVF vaccine products at Onderstepoort Biological Products (OBP) for future use in Eastern and Southern Africa. GALVmed also wishes to consider the feasibility of establishing an Africa wide RVF vaccine bank hosted by OBP in South Africa. In order to gain a
better understanding of potential issues and concerns, a Policy Landscaping Study was commissioned by GALVmed.
This is an output from the ‘Global Alliance For Livestock Veterinary Medicines (GALVmed): Phase 2 – Protecting Livestock and Saving Human Lives’ programme
Sinyangwe, Peter G. (2013) Policy Landscaping Study of RVF Control in Eastern and Southern Africa. GALVMed